UK-based Almac, a provider of contract services to pharmaceutical and biotech industries, has announced that it has expanded its MHRA/FDA approved UK commercial packaging facility, following its acquisition of a Noack N 623 blister packaging line from Romaco.
Almac manufacturing operations VP Geoff Sloan said blister size and dosage formats are becoming increasingly complex, in addition to product handling as innovative new molecules often require enhanced environmental controls.
"Through this acquisition, coupled with our immanent entry into the US commercial packaging market, we continue to expand our capabilities and flexibility to meet our client’s needs," Sloan said.
According to the company, the acquisition is to address the growing client demand for enhanced flexibility of larger blister sizes and innovative multi unit blister formats, besides a requirement for non permeability and enhanced environmental protection, particularly product humidity control.
Its automatic feeding system, filling inspection, ejection station and shorter set-up times enables the line to provide increased productivity, processing over 25,000 blisters per hour, including multi-product blisters.
The company provides services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRS technology (IVRS/IWRS), to commercial-scale manufacture.